Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Objective: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). Methods: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelin...

Full description

Bibliographic Details
Main Authors: Pranay Sinha, Anahita Mostaghim, Catherine G. Bielick, Angela McLaughlin, Davidson H. Hamer, Lee M. Wetzler, Nahid Bhadelia, Maura A. Fagan, Benjamin P. Linas, Sabrina A. Assoumou, Michael H. Ieong, Nina H. Lin, Ellen R. Cooper, Karrine D. Brade, Laura F. White, Tamar F. Barlam, Manish Sagar
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Tocilizumab
Sarilumab
Interleukin-6 inhibitors
Cytokine release syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220305683

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220305683

Similar Items